The role of chlorthalidone in patients with high-risk hypertension

Journal of Clinical Hypertension

Volumn 11, Issue 9, 2009, Pages 460-461

  Pitt, Bertram ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; DIURETIC AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ESSENTIAL HYPERTENSION; EVIDENCE BASED MEDICINE; HEART DEATH; HEART FAILURE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HIGH RISK PATIENT; HOSPITALIZATION COST; HUMAN; HYPERTENSION; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC HYPERTENSION; DRUG COMBINATION; RISK ASSESSMENT; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHLORTHALIDONE; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS;

EID: 70349973722     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00166.x     Document Type: Editorial

References (10)

1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981-2997. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
2. Davis B, Piller L, Cutler J. The role of diuretics in the prevention of heart failure: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation 2006, 113:2201-2210. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group
3. Grimm RH, Davis BR, Piller LB. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?. for the ALLHAT Collaborative Research Group
4. Jamerson K, Weber MA, Bakris GL. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
5. Jamerson K, Bakris G, Dahlof B. The comparison of 24-hour ambulatory and clinic blood pressure readings in the ACCOMPLISH trial. J Clin Hypertens
6. Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension 2007, 50:459-460.
7. Westendorp B, Hamming I, Szymanski MK. Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor. Eur J Pharmacol 2009, 602:373-379.
8. Eriksson JW, Jansson PA, Carlberg B. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study. Hypertension 2008, 52:1030-1037.
9. Ming-Sheng Z, Schulman I, Jaimes E. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008, 26:494-500.
10. Luscher TF, Wenzel RR, Moreau P. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995, 9(suppl 3):509-523.